Cancel
Rob Etherington
President & Chief Executive Officer
@
Clene Nanomedicine
zya@qv95h.96g
Sign up to see email
Known information
- Joined Actelion as founding Director of Marketing in 2000, the same year the company went public.
- Has nearly 30 years of sales, marketing, and leadership experience in the pharmaceutical industry.
- Worked for Actelion Pharmaceuticals, which was the largest biopharmaceutical company based in the EU until Johnson & Johnson Pharmaceuticals acquired the company in 2017.
- Served as the first U.S. commercial employee at Actelion, leading U.S. commercial operations and serving as Chair of the U.S. Commercial Strategic team.
- Was responsible for five marketed drugs at Actelion.
- Began his pharmaceutical career with a number of sales and marketing roles at Parke-Davis, a division of Pfizer.
- Oversaw the drug Lipitor as a Team Leader at Parke-Davis.
- As the founding CEO of Clene, has raised more than $150M in equity financings.
- Has driven Clene’s focus on neurodegenerative diseases.
About Clene Nanomedicine
Clene Nanomedicine is a biopharmaceutical company focused on developing nanotherapeutics for neurodegenerative diseases, with its lead candidate, CNM-Au8, targeting ALS, MS, and Parkinson's Disease.
Report inaccurate information
